INTRODUCTION
Chronic hepatitis C virus (HCV)b infection is a major public health problem, affecting over 2.7 million individuals in the U.S. and over 170 million worldwide [1, 2] . In the United States, HCV infection is the most common cause of chronic liver disease, accounts for 8,000 to 10 ,000 deaths annually, and is the leading indication for liver transplantation [3] . Since the initial discovery of HCV virus as the causative agent of non-A, non-B (NANB) hepatitis by Choo and colleagues in 1989 [4] , significant advances have been made in our understanding of its epidemiology, pathogenesis, diagnosis, and therapy. Increased understanding of the natural history of chronic infection will be essential in any effort to further elucidate pathogenetic mechanisms, predict clinical outcomes, and identify those patients for whom treatment is beneficial.
Acute infection with HCV virus is usually asymptomatic, and therefore infrequently diagnosed during this early period. Although up to one-third of patients may develop mild flu-like symptoms or jaundice, fulminant liver failure is very rare [5] . Despite vigorous humoral and cellmediated immune responses by the host, approximately 85 percent of patients fail to achieve spontaneous recovery and thus develop chronic infection, defined as a positive HCV antibody and RNA at six months. Chronic infection is typically characterized by a prolonged asymptomatic period, but will eventually lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma in 70 percent, 20 percent, and 4 percent of cases, respectively [6] . Mechanisms for HCV persistence remain unclear, but may involve viral mutation during replication, persistence in extrahepatic tissues, or formation of quasispecies that escape host immune response [7] [8] .
The natural history of HCV infection has been difficult to study. Accurate [10] [11] [12] [13] . While obviating the need for a prolonged follow-up period, these studies are limited by inherent uncertainties in time of disease onset, a systematic exclusion of infected patients who never seek medical attention due to spontaneous recovery or lack of symptoms, and a disproportionate inclusion of patients with particularly severe disease.
In 1990, Kiyosawa and colleagues [10] 
PROSPECTIVE STUDIES
Five studies have followed patients prospectively from the time of disease onset to histologically defined outcomes [14] [15] [16] [17] [18] , all in the setting of transfusionassociated NANB hepatitis. As expected, the inclusion of a wider spectrum of both healthy and symptomatic patients has resulted in numbers suggesting a lower rate of progression to end-stage liver disease (Table 2 ). These authors demonstrate that the development of complications is highly variable, but appears to be benign in most patients during the first decade of infection. These studies are limited, however, by the absence of controls, the intro- [23] and follow-up of healthy young German adults with prior transfusionassociated hepatitis [27] , suggesting that hepatitis C infection is likely associated with few, if any long-term complications in low-risk individuals.
More recently, Thomas and colleagues [28] prospectively evaluated the incidence and predictors of viral clearance and advanced liver disease in a community-based cohort of 919 patients who acquired HCV infection in the context of injection drug use. The authors recognized that injection drug use accounts for 60 percent of all new cases in the U.S. [29] , and that prior studies did not adequately evaluate clinical outcomes in this population, focusing instead on older transfusioninfected patients with multiple co-morbidities, or young, healthy immune globulin recipients. The authors found that after a median of 13.7 years of drug use and 8.8 years of follow-up, viral clearance occurred more frequently in nonblacks (OR 5.15) The effect of alcohol on fibrosis acceleration in patients with HCV infection is substantial even in moderate amounts; abstinence should be encouraged in most patients. Excessive amounts greater than 40 g/day in women and 60 g/day in men dramatically and independently increase the risk of cirrhosis [30] [31] . The mechanism remains unclear, but may involve altered host immune response to viral infection. Advanced age increases fibrosis progression significantly through heightened vulnerability to oxidative stress and diminished immune capacity. Statistical modeling has demonstrated that the probability of disease progression in men aged 61 to 70 was 300 times greater than for men aged between 21 to 40, highlighting its important place clinical decision-making [32] . Females have been found to have a ten-fold decreased progression rate than men at all ages, possible related to estrogen-mediated modulation of fibrogenesis [33] .
Co-infection with HIV is associated with accelerated fibrosis progression, particularly in those patients with low CD4 counts (<200 cells/ul) or concurrently drink alcohol [34] . Both of these risk factors accelerated the median expected time to cirrhosis to 16 years from 36 years in controls.
Co-infection with hepatitis B infection accelerates fibrosis and increases the risk of cirrhosis complicated by hepatocellular carcinoma [35] . Hepatitis A co-infection is usually self-contained but may increase the risk for developing fulminant hepatitis and hepatic failure [36] . Vaccination against hepatitis A and B should be performed routinely in previously unimmunized patients.
Although helpful in predicting response to interferon-based therapy, hepatitis C RNA and genotype do not correlate with progression of disease [37] [38] The formation of distinct but closely related viral mutants (quasispecies) within individual patients was-previously believed to be unrelated to severity of HCV-related liver disease. However, a recent investigation by Farci and colleagues suggests that examination of the genetic diversity of the virus during the first four months of infection may predict whether HCV infection will become chronic or resolve spontaneously [8] . The authors detected a marked increase in the genetic diversity of the hypervariable region 1 (HVR1) of the virus in patients with hepatitis that proved to be progressive. Conversely, patients whose infection eventually resolved demonstrated a decrease in genetic diversity of HVR1, as manifested by the mean number of nonsynonymous nucleotide substitutions per week. This raises the possibility that different modes of HCV transmission may result in critical differences in quasispecies generation and genetic diversity, thereby resulting in disparate clinical outcomes.
CONCLUSIONS
Chronic HCV infection remains a critical public health priority. Future morbidity, mortality, and cost resulting from hepatitis C-related care is expected to be astronomical, with a predicted 165,900 deaths from chronic liver disease, 27,200 deaths from hepatocellular carcinoma, and $10.7 billion in direct medical expenditures between 2010-2019 [39] . Based on current literature, we can safely predict that most patients with hepatitis C infection will develop chronic hepatitis, and that many of these patients will progress at variable rates toward cirrhosis and its complications. In midst of rapidly advancing therapies [40] and prospects of exciting new research animal models [41] , our facility in helping patients determine their individual risks for disease progression and suitability for treatment will be essential.
